DNA methyltransferase inhibitors in cancer: A chemical and therapeutic patent overview and selected clinical studies

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 12, 2012, Pages 1427-1442

  Fahy, Jacques ^a   Jeltsch, Albert ^b   Arimondo, Paola B ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Anticancer agents; DNA methylation; Epigenetics; Inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CP 4200; CURCUMIN; CYTIDINE DERIVATIVE; CYTOSINE DERIVATIVE; DISULFIRAM; DNA METHYLTRANSFERASE INHIBITOR; FLAVONOID; FLUCYTOSINE DEOXYRIBOSIDE; GENISTEIN; HYDRALAZINE; MG 98; N PHTHALOYLTRYPTOPHAN; NUCLEOSIDE DERIVATIVE; PROCAINAMIDE; PROCAINE; PSAMMAPLIN; RX 3117; SGI 1027; TETRAHYDROURIDINE; THIOPHENE DERIVATIVE; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMICAL COMPOSITION; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLON CANCER; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IC 50; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATENT; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DRUG DESIGN; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84869850999     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.729579     Document Type: Review

References (97)

1. Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389(6648):251-60
2. Margueron R, Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet 2010;11(4):285-96
3. Feng S, Jacobsen SE, Reik W. Epigenetic reprogramming in plant and animal development. Science 2010;330(6004):622-7
4. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science 2010;330(6004):612-16
5. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009;23(7):781-3
6. Bird A. Perceptions of epigenetics. Nature 2007;447(7143):396-8
7. Kouzarides T. Chromatin modifications and their function. Cell 2007;128(4):693-705
8. Mai A, Altucci L. Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009;41(1):199-213
9. Boumber Y, Issa JP. Epigenetics in cancer: What's the future? Oncology (Williston Park) 2011;25(3):220-6; 8
10. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447(7143):425-32
11. Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. ChemBioChem 2011;12(2):206-22
12. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39(4):457-66
13. Ji H, Ehrlich LI, Seita J, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010;467(7313):338-42
14. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41(12):1350-3
15. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41(2):178-86
16. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19(2):187-91
17. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31(1):27-36
18. Fournier A, Sasai N, Nakao M, Defossez PA. The role of methyl-binding proteins in chromatin organization and epigenome maintenance. Brief Funct Genomics 2012;11(3):251-64
19. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59
20. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7(1):21-33
21. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009;15(12):3938-46
22. Constantinides PG, Jones PA, Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 1977;267(5609):364-6
23. Constantinides PG, Taylor SM, Jones PA. Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 1978;66(1):57-71
24. Damaraju VL, Mowles D, Yao S, et al. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids 2012;31(3):236-55
25. Zhou L, Cheng X, Connolly BA, et al. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002;321(4):591-9
26. National Institute of Health. Inhibitor of DNA methylation. WO2003012051; 2003
27. National Institute of Health. Methylation inhibitor compounds. WO2005082144; 2005
28. University of Southern California. N4 modifications of pyrimidine analogs and uses thereof. WO2008054767; 2008
29. Byun HM, Choi SH, Laird PW, et al. 2'-Deoxy-N4-[2-(4-nitrophenyl) ethoxycarbonyl]-5-azacytidine: A novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett 2008;266(2):238-48
30. Medicine. MSSo. Azacytidine analogues and uses thereof. WO2009042766; 2009
31. Mount Sinai School of Medicine and Clavis Pharma. Azacytidine analogues and uses thereof. WO2009042767; 2009
32. Brueckner B, Rius M, Markelova MR, et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol Cancer Ther 2010;9(5):1256-64
33. Clavis Pharma second quarter and first half report 2011. Clavis Pharma press release. 2011.Available from: Http://www. clavispharma.com/news-events/ 2011-press-releases/clavis-second-quarterresults-2011 [Last accessed 29 August 2012]
34. Marquez VE, Lim MI, Treanor SP, et al. Cyclopentenylcytosine. A carboxylic nucleoside with antitumor and antiviral properties. J Med Chem 1988;31:1987-94
35. Rexan Corporation. Nucleoside derivatives and therapeutic use thereof. WO2005097757; 2005
36. Choi WJ, Chung HJ, Chandra G, et al. Fluorocyclopentenyl-cytosine with broad spectrum and potent antitumor activity. J Med Chem 2012;55(9):4521-5
37. Peters G, Smid K, Vecchi L, et al. Abstract 1770: Metabolism and mechanism of action of fluorocyclopentenylcytosine (RX-3117). Proceedings: AACR 103rd Annual Meeting 2012. Cancer Res 2012;72:8 Suppl 1. doi: 10.1158/1538-7445.AM2012-1770
38. Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117. Rexahn press release. 2012.Available from: Http://www.rexahn. com/cms/index.php/2012/03/rexahnpharmaceuticals-enrolls- first-subject-inexploratory-phase-i-clinical-study-of-rx-3117/ [Last accessed 22 June 2012]
39. Instytut Chemii Bioorganicznej PAN. A cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation. WO2011115513; 2011
40. Instytut Chemii Bioorganicznej PAN. Method of obtaining of 4-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition. WO2009067035; 2009
41. Southern Research Institute. The use of 2'-deoxy-4'-thiocytidine and its analogues as DNA hypomethylating anticancer agents. WO2011109012; 2009
42. SuperGen. Oligonucleotide analogues incorporating 5-aza-cytosine therein. WO2007041071; 2007
43. Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-Aza-2'- deoxycytidinecontaining dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 2010;9(5):1443-50
44. Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007;67(13):6400-8
45. A phase 1-2, dose escalation, multicenter study of two subcutaneous regimens of SGI-110, a DNA hypomethylating agent, in subjects with intermediate or high-risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). NCT01261312. ClinicalTrials.gov. 2010.Available from: Http://clinicaltrials.gov/ct2/show/NCT01261312? term=NCT01261312&rank=1 [Last accessed 20 July 2012]
46. Methylgene. Inhibitors of DNA methyltransferase. WO2006078752; 2006
47. SuperGen. Quinoline derivatives for modulating DNA methylation. WO2009049132; 2009
48. Denny WA, Atwell GJ, Baguley BC, Cain BF. Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles. J Med Chem 1979;22(2):134-50
49. Datta J, Ghoshal K, Denny WA, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 2009;69(10):4277-85
50. Foundation. UoLR. Therapeutic compounds. WO2008098077; 2008
51. Andrianasolo EH, France D, Cornell-Kennon S, Gerwick WH. DNA methyl transferase inhibiting halogenated monoterpenes from the Madagascar red marine alga Portieria hornemannii. J Nat Prod 2006;69(4):576-9
52. SuperGen. Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors. WO2010098866; 2010
53. DKFZ. Inhibitors of DNA methylation in tumor cells. EP1574449; 2005
54. Siedlecki P, Boy RG, Musch T, et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006;49(2):678-83
55. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65(14):6305-11
56. Cancer Research Technology Ltd. Phthalimides, succinimides and related compounds and their use as pharmaceuticals. WO2007007054; 2007
57. Curis, Inc. DNA methyl transferase inhibitors containing a zinc binding moiety. WO2008033744; 2008
58. Suzuki T, Tanaka R, Hamada S, et al. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg Med Chem Lett 2010;20(3):1124-7
59. Halby L, Champion C, Senamaud-Beaufort C, et al. Rapid synthesis of new DNMT inhibitors derivatives of procainamide. ChemBioChem 2012;13(1):157-65
60. Cornacchia E, Golbus J, Maybaum J, et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988;140(7):2197-200
61. Universidad Nacional Autonoma de Mexico. Hydralazine and procainamide use in cancer treatment as reactivators of the expression of tumor suppressor genes. 2002
62. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003;63(16):4984-9
63. INSERM. Substituted aminobenzoic acid derivatives as inhibitors of DNA methyltransferases. WO2012038417; 2012
64. Ohio State University Research Foundation. DNA methylation inhibitors. WO2012087889; 2012
65. Lin YS, Shaw AY, Wang SG, et al. Identification of novel DNA methylation inhibitors via a two-component reporter gene system. J Biomed Sci 2011;18:3
66. Fang MZ, Chen D, Sun Y, et al. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 2005;11(19 Pt 1):7033-41
67. INSERM. Flavones and flavanones derivatives as DNA methyltransferases inhibitors. WO2011029956; 2011
68. Dauzonne D, Folleas B, Martinez L, Chabot G. Synthesis and in vitro cytotoxicity of a series of 3-aminoflavones. Eur J Med Chem 1997;32(1):71-82
69. Gonzalez De Peredo A, Leonce S, Monneret C, Dauzonne D. Synthesis and biological evaluation of flavanones and flavones related to podophyllotoxin. Chem Pharm Bull (Tokyo) 1998;46(1):79-83
70. Bauvois B, Puiffe ML, Bongui JB, et al. Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13. J Med Chem 2003;46(18):3900-13
71. Liu Z, Xie Z, Jones W, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett 2009;19(3):706-9
72. Ohio State University. Curcumin compositions and uses thereof. WO2012024405; 2012
73. Pina IC, Gautschi JT, Wang GY, et al. Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003;68(10):3866-73
74. CNRS. Novel derivatives of psammaplin A, a method for their synthesis and their use for the prevention and treatment of cancer. WO2008125988; 2008
75. Baud MG, Leiser T, Haus P, et al. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J Med Chem 2012;55(4):1731-50
76. Jacobs University Bremen. Method and reagents for analyzing nucleic acid methylation reactions. PCTEP2008003779; 2008
77. Methylgene news release. 2006.Available from: Http://sedar.com/GetFile. do?lang=EN&docClass=8& issuerNo=00020670&fileName=/csfsprod/data75/ filings/01031676/00000001/s%3A%5Czzzseb% 5Cmeta1215.pdf [Last accessed 29 August 2012]
78. Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 2009;15(9):3177-83
79. Arce C, Segura-Pacheco B, Perez-Cardenas E, et al. Hydralazine target: From blood vessels to the epigenome. J Transl Med 2006;4:10
80. Psicofarma SA. Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment. 2009
81. Lin J, Haffner MC, Zhang Y, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 2011;71(4):333-43
82. Study of recurrent prostate cancer with rising prostate specific antigen (PSA) (NCT01118741). ClinicalTrials.gov. 2010.Available from: Http://clinicaltrials.gov/ct2/show/NCT01118741?term=dna +methyltransferase& rank=6 [Last accessed 18 July 2012]
83. 5-Fluoro-2'-deoxycytidine and tetrahydrouridine to treat patients with advanced cancer (NCT00359606). ClinicalTrials.gov. 2006. Available from: Http://clinicaltrials.gov/ct2/show/NCT00359606?term=dna +methyltransferase& rank=25 [Last accessed 18 July 2012]
84. FdCyd and THU for advanced solid tumors (NCT01534598). ClinicalTrials. gov. 2012.Available from: Http://clinicaltrials.gov/ct2/show/NCT01534598?term= dna +methyltransferase&rank=26 [Last accessed 18 July 2012]
85. A multi-histology phase II study of 5-fluoro-2-deoxycytidine with tetrahydrouridine (FdCyd + THU) (NCT00978250). ClinicalTrials.gov. 2009.Available from: Http://clinicaltrials.gov/ct2/show/NCT00978250?term=dna +methyltransferase&rank=23 [Last accessed 18 July 2012]
86. A phase 2, randomized, open-label study of azacitidine (Vidaza) vs MGCD0103 vs azacitidine in combination with MGCD0103 for the treatment of elderly subjects with newly diagnosed AML or intermediate-2 or high-risk MDS (NCT00666497). ClinicalTrials.gov. 2008.Available from: Http://clinicaltrials. gov/ct2/show/NCT00666497?term=dna +methyltransferase&rank=5 [Last accessed 18 July 2012]
87. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1(7):598-607
88. Randomized phase II trial of adjuvant combined epigenetic therapy with azacitidine and entinostat in resected stage I Non-small Cell Lung Cancer versus standard care (NCT01207726). ClinicalTrials.gov. 2010.Available from: Http://clinicaltrials.gov/ct2/show/NCT01207726?term=dna +methyltransferase& rank=17 [Last accessed 18 July 2012]
89. A phase I study of oral azacitidine as a single agent and in combination with carboplatin or ABI-007 in subjects with relapsed or refractory solid tumors (NCT01478685). ClinicalTrials.gov. 2011.Available from: Http://clinicaltrials. gov/ct2/show/NCT01478685? term=dnmt&rank=7 [Last accessed 18 July 2012]
90. Induction therapy with decitabine and plerixafor priming for patients ‡ 60 years with Acute Myeloid Leukemia (NCT01352650). ClinicalTrials.gov. 2011.Available from: Http://clinicaltrials.gov/ct2/show/NCT01352650?term=dna +methyltransferase&rank=7 [Last accessed 18 July 2012]
91. Targeted demethylation to enhance response or overcome resistance to EGFR blocking agents in KRAS wild-type metastatic colorectal cancer patients using sequential decitabine and panitumumab (NCT00879385). ClinicalTrials.gov. 2009.Available from: Http://clinicaltrials.gov/ct2/show/NCT00879385?term=dna +methyltransferase&rank=3 [Last accessed 18 July 2012]
92. A proof of concept study of non-DNA damaging DNMT1 depletion therapy for myelodysplastic syndrome (NCT01165996). ClinicalTrials.gov. 2010.Available from: Http://clinicaltrials.gov/ct2/show/NCT01165996? term=dnmt&rank=2 [Last accessed 18 July 2012]
93. Inhibition of DNA methylation by 1-hr infusion of 5-aza-2'-deoxycitidine (decitabine) x 10 days (M-F) with escalating doses of SC pegylated (PEG) Interferon-alfa 2B: A phase I study with molecular correlates (NCT00701298). ClinicalTrials.gov. 2008.Available from: Http://clinicaltrials.gov/ct2/show/ NCT00701298? term=dnmt&rank=10 [Last accessed 18 July 2012]
94. Phase I/II Trial of tamoxifen following epigenetic regeneration of estrogen receptor using decitabine and LBH 589 in patients with triple negative metastatic breast cancer (NCT01194908). ClinicalTrials.gov. 2008.Available from: Http://clinicaltrials.gov/ct2/show/NCT01194908? term= epigenetic+AND+cancer&rank=15 [Last accessed 19 July 2012]
95. Jia D, Jurkowska RZ, Zhang X, et al. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007;449(7159):248-51
96. Song J, Rechkoblit O, Bestor TH, Patel DJ. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 2011;331(6020):1036-40
97. Song J, Teplova M, Ishibe-Murakami S, Patel DJ. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science 2012;335(6069):709-12